Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00QDJ
|
|||
| Drug Name |
Trametinib
|
|||
| Synonyms |
GSK 1120212; GSK-1120212; GSK1120212; JTP 74057; JTP-74057; Mekinist; Trametinib (GSK1120212); Trametinib (GSK1120212JTP 74057); Trametinib (MEK inhibitor); 33E86K87QN; A1-01871; AK174783; CHEBI:75998; UNII-33E86K87QN
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Metastatic melanoma [ICD-11: 2E2Z; ICD-10: C76-C80] | Approved | [1] | |
| Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] | Investigative | [2] | ||
| Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] | Investigative | [2] | ||
| Therapeutic Class |
Antiviral Agents
|
|||
| Company |
GlaxoSmithKline
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C26H23FIN5O4
|
|||
| Canonical SMILES |
CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5
|
|||
| InChI |
1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)
|
|||
| InChIKey |
LIRYPHYGHXZJBZ-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 871700-17-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
23798664, 75249284, 117699169, 123051062, 126731327, 135268431, 135626893, 136340158, 136349545, 136367676, 136367930, 136920397, 137276024, 141572077, 151990047, 152258297, 160647136, 160708513, 160778567, 162011387, 162038081, 162202634, 163912759, 164034383, 164041722, 164193929, 164347444, 164778700, 172087062, 172913906, 174531132, 175265958, 175427149, 177749430, 178103109, 186006546, 198992932, 223377627, 223683763, 223993724, 226532429, 242059762, 243331820, 246343852, 249814536, 251971376, 252109931, 252126268, 252160429, 252215501
|
|||
| ChEBI ID |
CHEBI:75998
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | HUMAN ERK activator kinase 1 (MEK1) | Target Info | Inhibitor | [2] |
| HUMAN ERK activator kinase 2 (MEK2) | Target Info | Inhibitor | [2] | |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 2 | Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.